Nuvectis Pharma's primary business segment focuses on the research, development, and clinical evaluation of novel small molecule therapeutics for the treatment of various cancers. The company's R&D activities are centered around two lead product candidates: NXP800, targeting ARID1a-mutated ovarian carcinoma, and NXP900, a c-Src and YES1 kinase inhibitor. The company utilizes advanced drug discovery techniques and collaborates with research institutions and clinical trial organizations to advance its pipeline. This segment addresses significant unmet medical needs in oncology, aiming to improve patient outcomes through targeted therapies. Nuvectis Pharma is strategically positioned to capitalize on the growing demand for precision medicines in oncology, with future opportunities including expanding its pipeline and securing regulatory approvals for its lead candidates. The company has partnerships with organizations like ENGOT and GOG Foundation to conduct clinical trials. Regulatory and clinical aspects include Phase 1b trials for NXP800 and Phase 1a trials for NXP900.